Literature DB >> 6278948

Renal parathyroid hormone receptors in the chick: downregulation in secondary hyperparathyroid animal models.

L R Forte, S G Langeluttig, R E Poelling, M L Thomas.   

Abstract

We characterized the binding of 125I-[Nle8, Nle18, Tyr34]parathyroid hormone-(1-34) amide [125I-nlPTH-(1-34)] to renal plasma membranes prepared from chicks to determine the effects of secondary hyperparathyroid states on renal PTH receptors. This radioligand exhibited specific binding to membranes with high affinity (Kd, 2-3 X 10(-9) M). Agonists or competitive antagonists of PTH were effective in competing for binding sites labeled with 125I-nlPTH-(1-34), whereas an inactive fragment of PTH, salmon calcitonin, and bovine growth hormone did not compete with the radioligand for renal PTH receptors. Newly hatched chicks raised on control diet with adequate vitamin D and calcium or diets deficient in either vitamin D or calcium were used to study the regulation of renal PTH receptors in experimental models of secondary hyperparathyroidism. We found that both experimental diets resulted in marked hypocalcemia and progressive loss of renal cyclic AMP responsiveness to PTH in vitro. Associated with this refractoriness to the hormone was a marked reduction in PTH receptors in membranes from both vitamin D-deficient and calcium-deficient chick kidney. No change in the affinity of the PTH receptors was found. Vitamin D3, in a single dose of 250 micrograms, partially restored serum calcium of vitamin D-deficient birds toward normal by 72 h and also partly restored renal cyclic AMP responsiveness to PTH and the PTH receptor number toward control values. We conclude that renal refractoriness to PTH observed in experimentally hyperparathyroid animals models is due to a marked loss of plasma membrane receptor sites for PTH without an apparent change in the affinity of the receptors for the hormone.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6278948     DOI: 10.1152/ajpendo.1982.242.3.E154

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  8 in total

1.  Na,K-ATPase activity and 25(OH)vitamin D3 hydroxylation in rat proximal tubules.

Authors:  D Elstein; J Silver
Journal:  Pflugers Arch       Date:  1986-10       Impact factor: 3.657

2.  Effects of vitamin D and parathyroid hormone on cyclic AMP production by bone cells isolated from rat calvariae.

Authors:  J A Crowell; C W Cooper; S U Toverud; A Boass
Journal:  Calcif Tissue Int       Date:  1984-05       Impact factor: 4.333

3.  Desensitization to parathyroid hormone in renal cells from aged rats is associated with alterations in G-protein activity.

Authors:  H Hanai; C T Liang; L Cheng; B Sacktor
Journal:  J Clin Invest       Date:  1989-01       Impact factor: 14.808

4.  Canine renal receptors for parathyroid hormone. Down-regulation in vivo by exogenous parathyroid hormone.

Authors:  C A Mahoney; R A Nissenson
Journal:  J Clin Invest       Date:  1983-08       Impact factor: 14.808

5.  Effects of dietary-induced hyperparathyroidism on the parathyroid hormone-receptor-adenylate cyclase system of canine kidney. Evidence for postreceptor mechanism of desensitization.

Authors:  J Tamayo; E Bellorin-Font; K J Martin
Journal:  J Clin Invest       Date:  1983-08       Impact factor: 14.808

6.  Rapid development of renal resistance to low doses of synthetic bovine parathyroid hormone fragment 1-34. Dissociation of urinary cyclic adenosine monophosphate, phosphaturic, and calciuric responses.

Authors:  W M Law; H Heath
Journal:  J Clin Invest       Date:  1983-09       Impact factor: 14.808

7.  Functional characterization and evolution of PTH/PTHrP receptors: insights from the chicken.

Authors:  Pedro L C Pinheiro; João C R Cardoso; Deborah M Power; Adelino V M Canário
Journal:  BMC Evol Biol       Date:  2012-07-06       Impact factor: 3.260

Review 8.  CCL2/Monocyte Chemoattractant Protein 1 and Parathyroid Hormone Action on Bone.

Authors:  Jawed Akhtar Siddiqui; Nicola C Partridge
Journal:  Front Endocrinol (Lausanne)       Date:  2017-03-29       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.